Sana Biotechnology (NASDAQ:SANA) Shares Gap Up to $4.66

Sana Biotechnology, Inc. (NASDAQ:SANA)’s share price gapped up prior to trading on Friday . The stock had previously closed at $4.66, but opened at $5.00. Sana Biotechnology shares last traded at $5.23, with a volume of 164,497 shares trading hands.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on SANA shares. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Sana Biotechnology in a research report on Thursday, May 9th. Rodman & Renshaw initiated coverage on Sana Biotechnology in a report on Wednesday, June 26th. They issued a “buy” rating and a $16.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, Sana Biotechnology presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.75.

Sana Biotechnology Price Performance

The stock has a fifty day simple moving average of $5.95 and a two-hundred day simple moving average of $7.52. The firm has a market capitalization of $1.16 billion, a P/E ratio of -3.44 and a beta of 1.45.

Sana Biotechnology (NASDAQ:SANA) last issued its earnings results on Wednesday, May 8th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). As a group, sell-side analysts expect that Sana Biotechnology, Inc. will post -1.15 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Victory Capital Management Inc. acquired a new stake in shares of Sana Biotechnology in the 4th quarter worth about $54,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Sana Biotechnology by 42.1% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,257 shares of the company’s stock valued at $66,000 after purchasing an additional 4,815 shares during the last quarter. Simplex Trading LLC boosted its holdings in shares of Sana Biotechnology by 31.3% in the 4th quarter. Simplex Trading LLC now owns 18,080 shares of the company’s stock worth $73,000 after buying an additional 4,313 shares during the last quarter. E Fund Management Co. Ltd. grew its position in Sana Biotechnology by 40.0% during the fourth quarter. E Fund Management Co. Ltd. now owns 23,361 shares of the company’s stock valued at $95,000 after buying an additional 6,673 shares during the period. Finally, SG Americas Securities LLC purchased a new position in Sana Biotechnology in the fourth quarter valued at about $99,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.